|
⚲
|
| Keyboard |
| Bridger Management LLC
✚
|
|
|---|---|
| CRD # | 160738 |
| SEC # | 801-74245 |
| CIK # | 0001166309 |
| AUM | 485.2 M (2026-03-27) |
| Employees | 8 (62% Investors, 0% Brokers) |
| Phone | 212-984-2125 |
| Address | 90 Park Avenue 40th Fl New York, NY 10016 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Morgan Stanley | 0.0 | ||
| Amazon Com Inc | 0.0 | ||
| Teva Pharmaceutical Industries Ltd | 0.0 | ||
| Stars Group Inc | 0.0 | ||
| Dexcom Inc | 0.0 | ||
| Alcon Inc | 0.0 | ||
| Nike Inc | 0.0 | ||
| Alphabet Inc | 0.0 | ||
| Visa Inc | 0.0 | ||
| Churchill Downs Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Bridger Healthcare SIV I LP | [2022-02-25] | 17.5 M | 1.4 M |
| Filed 2024-11-27 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Bridger Healthcare SIV I LP | 2021-11-29 | 17.5 M | |
| HF | Swiftcurrent Master Fund Ltd | [2021-11-29] | 1,371.3 M | 297.6 M |
| Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Auson Holdings LLC | [2018-10-08] | 76.8 M | 125.3 M |
| Filed 2025-07-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Bridger Healthcare Ltd | [2014-11-28] | 235.0 M | 0.3 M |
| Filed 2023-06-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Swiftcurrent Offshore Master Ltd | [2014-03-31] | 2,337.8 M | 523.0 M |
| Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| Other | ALEA Partners LLC | 2012-02-15 | 10.0 M | |
| PE | Bridger Horizon Vietnam Partners LP | [2012-02-15] | 1.1 M | |
| Other | North Forty Partners LLC | 2012-02-15 | 28.9 M | |
| HF | Swiftcurrent Offshore Ltd | [2012-02-15] | 2,337.8 M | 1,610.2 M |
| Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 0.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 0.5 |
| By Discretionary | ||
| Discretionary | 3 | 0.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 0.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.4 | |
| United States Persons | 0.1 | |
| Total | 3 | 0.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Robert Meschi | Director | 143 | 22 | |
| Brian Eden | Director | 36 | 15 | |
| Lucas Warford | Executive Officer | 8 | 3 | |
| Neil Cammarosano | Director, Executive Officer | 7 | 3 | |
| Bridger Management LLC | Promoter | 7 | 2 | |
| Roberto Mignone | Executive Officer, Promoter | 6 | 2 | |
| Michael Tierney | Executive Officer | 4 | 2 | |
| Blake Goodner | Promoter | 3 | 2 | |
| Matthew Truax | Director, Executive Officer | 3 | 1 | |
| Bridger Capital LLC | Executive Officer | 2 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001166309] | |
| 3 | [0001166309] | |
| 4 | [0001166309] | |
| SC 13D | [0001166309] | |
| SC 13G | [0001166309] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $2.8B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | JM1U681K2Z42HG324E45 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2016-11-11 | Buy | 322,472 | $3.08 | 993,214 |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-18 | Disposed to issuer | 2,841,255 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-18 | Disposed to issuer | 1,793,745 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-17 | Disposed to issuer | 147,060 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-17 | Disposed to issuer | 232,940 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-16 | Disposed to issuer | 183,905 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-16 | Disposed to issuer | 116,095 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-13 | Disposed to issuer | 47,900 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-13 | Disposed to issuer | 547,100 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-11 | Disposed to issuer | 30,000 | $0.00 | |
|
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
|
2015-11-10 | Disposed to issuer | 60,000 | $0.00 | |
|
Cardiff Oncology Inc TROV
Common Stock, $0.0001 par value per share
|
2015-07-17 | Buy | 140,000 | $8.75 | 1,225,000 |
|
Response Genetics Inc RGDX
Warrants (right to buy) · derivative
|
2015-04-03 | Other | 1,351,352 | ||
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-04-02 | Buy | 300,000 | $6.90 | 2,070,000 |
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-02-27 | Buy | 79,343 | $5.62 | 445,908 |
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-02-26 | Buy | 78,801 | $5.42 | 427,101 |
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-02-25 | Buy | 105,142 | $5.12 | 538,327 |
|
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
|
2015-02-06 | Buy | 444,444 | $4.50 | 1,999,998 |
|
Response Genetics Inc RGDX
Common Stock, par value $.01 per share
|
2012-09-13 | Buy | 3,000,000 | $1.10 | 3,300,000 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Endowment Advisers LP
✚
|
TX | 499.7 M |
|
Riposte Capital LLC
✚
|
NY | 496.6 M |
|
Basin Oil and Gas Management LP
✚
|
TX | 492.7 M |
|
OnyxPoint Global Management LP
✚
|
NY | 481.2 M |
|
Lion Point Capital LP
✚
|
NY | 480.6 M |
|
JW Asset Management LLC
✚
|
476.9 M | |
|
Sycale Advisors NY LLC
✚
|
NY | 473.1 M |
|
AOF Management LLC
✚
|
CA | 461.5 M |
|
Saybrook Fund Advisors LLC
✚
|
CA | 461.2 M |
|
Harspring Capital Management LLC
✚
|
NY | 459.1 M |